USO 23251

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)(D9722C00001)

Disease Types: Breast Cancer Research

Eligibility Requirements:

Adult females, pre/peri-menopausal and/or post-menopausal, and adult males

Histologically or cytologically documented diagnosis of HR-positive, HER2-negative breast cancer

Advanced breast cancer with either locally advanced disease not amenable to curative treatment or metastatic disease

ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks

FFPE tumour tissue from each participant

Documented germline tumour loss of function mutation in BRCA1, BRCA2, or PALB2

Adequate organ and marrow function

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg